J. OH33 reported that the decreased METTL3 expression leads to reduced SRSF11 expression in breast cancer (BRCA), Colon adenocarcinoma (COAD), lung adenocarcinoma (LUAD), and stomach adenocarcinomas (STAD). Here, METTL3 is linked to gastric adenocarcinoma.